ID
12780
Description
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00581607
Link
https://clinicaltrials.gov/show/NCT00581607
Keywords
Versions (1)
- 12/21/15 12/21/15 -
Uploaded on
December 21, 2015
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Sarcoidosis NCT00581607
Eligibility Sarcoidosis NCT00581607
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Vasodilator Agents; calcium channel blocker
Data type
boolean
Alias
- UMLS CUI [1]
- C0042402
- UMLS CUI [2]
- C0006684
Description
Airway Obstruction; fev1
Data type
boolean
Alias
- UMLS CUI [1]
- C0001883
- UMLS CUI [2]
- C0588029
Description
who class
Data type
boolean
Alias
- UMLS CUI [1]
- C0451584
Description
pregnant; lactating
Data type
boolean
Alias
- UMLS CUI [1,1]
- C2828358
- UMLS CUI [1,2]
- C0549206
Description
left ventricular dysfunction
Data type
boolean
Alias
- UMLS CUI [1]
- C0242698
Description
cardiac index; right atrial pressure
Data type
boolean
Alias
- UMLS CUI [1]
- C0428776
- UMLS CUI [2]
- C0456165
Description
liver dysfunction
Data type
boolean
Alias
- UMLS CUI [1]
- C0086565
Description
compliance behavior limited comorbidity
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1321605
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Description
walking
Data type
boolean
Alias
- UMLS CUI [1]
- C0080331
Similar models
Eligibility Sarcoidosis NCT00581607
- StudyEvent: Eligibility
C0018795 (UMLS CUI [2])
C0036202 (UMLS CUI [1,2])
C0006684 (UMLS CUI [2])
C0588029 (UMLS CUI [2])
C0549206 (UMLS CUI [1,2])
C0456165 (UMLS CUI [2])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
No comments